University of Missouri researchers are working to develop the first-ever vaccine proven to protect cattle from a devastating tick-borne cattle disease known as bovine anaplasmosis. The research is vital to the state’s economy as it aims to protect Missouri’s $1.6 billion cattle industry.
Bovine anaplasmosis — which is common in Missouri — infects the red blood cells of cattle and causes hundreds of millions of dollars in economic losses nationwide each year and nearly $1 billion in losses worldwide, primarily due to reduced cattle production, treatment costs and deaths.
Roman Ganta, a McKee endowed professor in Mizzou’s College of Veterinary Medicine and a Bond Life Sciences Center researcher, led the study that created the new vaccine. The work involved genetically modifying the pathogen Anaplasma marginale — which causes bovine anaplasmosis — in a lab. By deleting a specific gene and then injecting the modified pathogen into cattle, the vaccinated cattle were successfully immunized against the disease.
“I often receive calls from cattle producers who are excited about our research and want to know how soon they can get the vaccine,” Ganta said. “There is currently no effective, widely available, vaccine for the disease, and cattle farmers are very worried about the disease harming or killing their cattle. We want to help farmers in Missouri and around the world and are working hard to come up with a viable solution.”
Working at a land-grant university, Ganta’s research will ultimately help improve the health of cattle — and the agricultural economy — throughout Missouri, particularly in rural areas.
“Missouri is a hotbed for tick-borne diseases, and bovine anaplasmosis causes massive economic losses both here in Missouri and around the world,” Ganta said. “Mizzou has already made substantial contributions to protecting cattle against ticks. For example, many farmers currently give their cattle an antibiotic called chlortetracycline, which was first discovered at Mizzou’s Sanborn Field in 1945. While effective, that medicine doesn’t fully eliminate the infection, so this new vaccine is an innovative step forward to fully eliminate the infection.”
Ganta said the new vaccine has been proven to give immunized cattle protection against bovine anaplasmosis for at least a month, and he and his team are eager to conduct additional research to determine how long the genetically modified pathogen can provide immunity for cattle. Ganta is also collaborating with industry partners to discuss future distribution of the new vaccine — which has been patented — to cattle producers.
“The genetically modified live vaccine offers protective immunity against wild-type Anaplasma marginale tick-transmission challenge” was published recently in Vaccine. Funding for the study was provided by the National Institutes of Health and Russell L. Rustici Rangeland and Cattle Research Endowment, University of California, Davis.
